

Planned by Some of Oncology's Best and Brightest



Bruce Johnson, MD, FASCO
Dana-Farber Cancer Institute
Chair, Co-Host Committee (ASCO)



Melvin Chua, MBBS, FRCR, PhD
National Cancer Centre of Singapore
Chair, Program Committee



Lillian L. Siu, MD, FRCPC, FASCO
Princess Margaret Cancer Centre
Immediate Past Chair, Program Committee



Takayuki Yoshino, MD, PhD
National Cancer Center Hospital East
Member, Co-Host Committee (JSCO)



Hironobu Minami, MD, PhD
Kobe University Graduate School of Medicine
Member, Co-Host Committee (JSMO)



Howard A. Burris III, MD, FACP, FASCO
Sarah Cannon Research Institute
Chair, Advisory Committee (ASCO)

American Society of Clinical Oncology
2318 Mill Road, Suite 800
Alexandria, VA 22314



Exhibits and Industry Expert Theater

Exhibiting companies will be onsite to showcase their innovations in technology (e.g., imaging, robotics, big data/large language models/AI, precision medicine, nanotechnology, wearables) which create solutions in providing optimal care to patients.

ASCO® Breakthrough™

HOTEL RESERVATION AND EARLY REGISTRATION DEADLINE
June 26, 2024, at 11:59 PM (ET)



Shining a Light on Advances in Cancer Care

August 8–10, 2024

PACIFICO Yokohama North | Yokohama, Japan & Online
asco.org/btregister

#ASCOBT24

REGISTRATION AND HOTEL RESERVATIONS

asco.org/btregister



HOTEL RESERVATION AND EARLY REGISTRATION DEADLINE
June 26, 2024, at 11:59 PM (ET)

QUESTIONS?

Registration: btregistration@spargoinc.com

Hotel Reservation: bthousing@spargoinc.com

Phone: 888-788-1522 (within the U.S.) or
+1-703-449-6418 (outside the U.S.)

Hours of Operation: 8:30 AM–5:00 PM (ET)

Co-Hosts




ASCO Breakthrough Returns to Asia!

Together with our co-host societies and regional collaborators, ASCO is thrilled to connect practicing clinicians, oncology thought leaders, med-tech pioneers, and research trailblazers to spark new conversations and partnerships that transcend disciplines and nations.



WHAT MAKES THIS A CAN'T-MISS MEETING?

- ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites.
- Multidisciplinary experts will break down how to seamlessly integrate these discoveries into your practice, enhancing patient care and treatment outcomes.
- Our global forum will inspire collaborations and transformative solutions to ensure the highest quality and equitable care for all people affected by cancer.



Program Highlights



KEYNOTE SPEAKERS



Andrew Trister, MD, PhD



Shimon Sakaguchi, MD, PhD



Raffaella Casolino, MD, PhD

Featured Sessions

**All times are JST.*

Artificial Intelligence in the Cancer Clinic

Thursday, August 8 | 15:45–17:00

Dive into AI's impact on cancer care in this session covering current uses.

Alexander T. Pearson, MD, PhD—Chair
University of Chicago
Artificial Intelligence in Action: Progress and Successes in the Clinic

Joe Poh Sheng Yeong, PhD, MBBS
Singapore General Hospital
Artificial Intelligence–Assisted Pathomics for Clinical Research and Precision Medicine

Danielle S. Bitterman, MD
Brigham and Women's Hospital
Large Language Models for Applications in the Clinic

Arsela Prelaj, MD
Fondazione IRCCS Istituto Nazionale Tumori
Artificial Intelligence–Driven Data Platform for Individualizing Therapies: Experience of I3LUNG Study

Balancing Health Economics With New Cancer Treatments

Friday, August 9 | 17:00–18:00

Navigate the intersection of health economics and cancer care with a diverse panel addressing global disparities.

Natasha B. Leighl, MD, FASCO—Chair
Princess Margaret Cancer Centre
Global Disparities in Cancer Care Accessibility

Lydia Loke, MPH
Ministry of Health Holdings
Cancer Treatment Inequity in High-Income Countries

Johannes J. Fagan, MBChB., FCS. (SA.), MMed (Otol)
University of Cape Town Medical School
Tackling Cancer Care Inaccessibility in Low- and Middle-Income Countries

The Future of Immunotherapy: New Drugs and New Ideas

Saturday, August 10 | 10:15–11:30

Discover the future of immunotherapy in cancer care from a multidisciplinary panel of global experts.

Philip D. Greenberg, MD—Chair
Fred Hutchinson Cancer Research Center
Moving Beyond PD1: The Science and Rationale for New Targets

Brigette Ma, MD
The Chinese University of Hong Kong
Novel Targets and Combinations

Lin Shen, MD, PhD
Peking University Cancer Hospital and Institute
Cell Therapy in Solid Tumors

Niels W.C.J. van de Donk, MD, PhD
Amsterdam University Medical Center, Vrije Universiteit Amsterdam
T-Cell Engaging Bispecifics in Cancer